Research
Hormonal
Resveratrol, a SIRT1 activator, counteracts adverse consequences of a high-calorie diet in mice, including extending lifespan and improving metabolic health, by promoting mitochondrial biogenesis.
Resveratrol has shown benefits in mice on high-calorie diets by activating SIRT1 and improving mitochondrial function. However, human evidence is limited to short-term metabolic improvements, and the mechanism of action is debated. It is not a substitute for a healthy diet and lifestyle.
ModerateSupportsMEDIUM confidence
Interestingly, two studies showed that dosing mice with resveratrol counteracted some of the adverse consequences of a high fat/high calorie diet, including shortened life span... One of these studies went on to show that the mice fed resveratrol underwent a considerable expansion in mitochondrial number in muscle.
Why this rating
Strong effects in mice, but human data is limited to short-term metabolic markers, and the mechanism of SIRT1 activation by resveratrol is controversial.
Source
Sirtuins in Aging and Disease
Leonard Guarente · Cold Spring Harbor Symposia on Quantitative Biology · 2007
DOI 10.1101/sqb.2007.72.024
narrative_reviewCited 373×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Calorie restriction extends lifespan in yeast, C. elegans, and Drosophila by activating sirtuins (Sir2/SIRT1), which are NAD-dependent deacetylases that link metabolic state to aging.Good
- SIRT1 activation via calorie restriction or resveratrol promotes mitochondrial biogenesis through PGC-1α deacetylation, which may reduce reactive oxygen species (ROS) production and mitigate aging.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →